MOB:+8617734410222

Enobosarm
Ostarine.svg
Clinical data
Synonyms GTx-024; MK-2866; Ostarine; S-22[1]
Routes of
administration
By mouth
ATC code
  • none
Legal status
Legal status
Pharmacokinetic data
Elimination half-life 24 hours[citation needed]
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C19H14F3N3O3
Molar mass 389.33 g/mol g·mol−1
3D model (JSmol)
Melting point 132 to 136 °C (270 to 277 °F)
Enobosarm, also known as ostarine, is an investigational selective androgen receptor modulator (SARM) developed by GTx, Inc. for the treatment of conditions such as muscle wasting and osteoporosis, formerly under development by Merck & Company.

According to a 2009 paper authored by GTx, "Readers are cautioned to note that the name ostarine is often mistakenly linked to the chemical structure of [S-4], which is also known as andarine. The chemical structure of ostarine has not been publicly disclosed."[2] A 2009 review stated "Recently, GTx disclosed that compound 5 had advanced into clinical trials. The patent application described detailed data in an initial proof-of-concept Phase IIa clinical trial. It is not explicitly stated that compound 5 is Ostarine (MK-2866).[3]

As of now, the mechanism of action of Enobosarm is still being debated and requires further investigation.



           

Copyright © 2014-2024 HEBEI SHUOXI BIOTECHNOLOGY CO., LTD. Power by DedeCms